Showing 6371-6380 of 9943 results for "".
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- Above-the-Neck Melanoma More Likely to Spreadhttps://practicaldermatology.com/news/above-the-neck-melanoma-more-likely-to-spread/2460176/Malignant melanoma above the neck is more likely to spread, according to new findings presented at the 28th European Dermato-Venereology Society Congress in Madrid. New results from a descriptive, 6-month clinical study suggest that malignant melanoma that develops on the ne
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- It's Grant Time: La Fondation La Roche-Posay Calls for Scientific Abstractshttps://practicaldermatology.com/news/its-grant-time-la-fondation-la-roche-posay-calls-for-scientific-abstracts/2460169/Calling all residents, fellows, and practitioners within their first five years of practice: La Fondation La Roche-Posay (North American) is now accepting submissions for their 2020 grants program. Three grants for $10,000, $5,000 & $5,000 will be awarded for innovative program
- Study: Tape Strips Can Assess Biomarkers in Pediatric ADhttps://practicaldermatology.com/news/study-tape-strips-can-assess-biomarkers-in-pediatric-ad-1/2460167/Tape strips may serve as a minimally invasive approach to assess biomarkers for early-onset pediatric atopic dermatitis (AD), finds a study in JAMA Dermatology. In the study of 51 children younger than 5 years, 21 children had moderate to severe AD with less than 6 months of di
- With New Funding, Turn Therapeutics Will Launch Phase 4 Study of AD Drughttps://practicaldermatology.com/news/with-new-funding-turn-therapeutics-will-launch-phase-4-study-of-ad-drug/2460162/Turn Therapeutics has closed its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX Eczema Emulsion, with enrollment scheduled to begin in Q1 2020. The series B financing will also support advancement of additional i
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherap
- Study: Recell System Plus Dermabrasion Speeds Acne Scar Healinghttps://practicaldermatology.com/news/study-recell-system-plus-dermabrasion-speeds-acne-scar-healing/2460154/When combined with dermabrasion, the RECELL Autologous Cell Harvesting Device speeds the healing of facial acne scars, according to a study in Aesthetic Plastic Surgery. The RECELL System uses a small
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the
- Study: Long-Term Use of Brodalumab Is Safe, Effectivehttps://practicaldermatology.com/news/study-long-term-use-of-brodalumab-is-safe-effective/2460150/Long-term use of brodalumab (SILIQ) improved skin clearance and quality of life in patients with moderate-to-severe psoriasis, according to a new study in the American Journal of Clinical Dermatology. Ov